Adjuvant Effects of Fermented Red Ginseng Extract on Advanced Non-Small Cell Lung Cancer Patients Treated with Chemotherapy

被引:0
作者
JIANG Shu-long [1 ,2 ]
LIU Hong-jie [3 ]
LIU Zhao-chun [4 ]
LIU Ning [2 ]
LIU Rui [1 ]
Young-Reep Kang [5 ]
Joong-Gu Ji [6 ]
ZHANG Chao [7 ]
HUA Bao-jin [1 ]
Shin-Jyung Kang [8 ]
机构
[1] Department of Oncology,Guang'anmen Hospital,China Academy of Chinese Medical Sciences
[2] Department of Oncology,Jining First People's Hospital
[3] School of Medicine,Jinan University
[4] Institute of International Education,Shandong University of Traditional Chinese Medicine
[5] Industry-Academic Cooperation Foundation (IACF),Joongbu University
[6] Department of Oriental Health Care,Joongbu University
[7] Department of Stomatology,Jining First People's Hospital
[8] Department of Herbal Pharmaceutical Science,Joongbu University
关键词
lung cancer; Korean red ginseng; fermented red ginseng extract; chemotoxicity; tumor adjuvant therapy; Chinese medicine;
D O I
暂无
中图分类号
R734.2 [肺肿瘤];
学科分类号
100214 ;
摘要
Objective: To investigate the adjuvant therapeutic effects of fermented red ginseng(FRG) extract on non-small cell lung cancer(NSCLC) patients treated with chemotherapy. Methods: A total of 60 patients with advanced NSCLC were assigned to two groups using a random number table, i.e., the gemcitabine plus cisplatin(GP) chemotherapy alone group(26 patients) and the FRG + GP chemotherapy group(34 patients), for 60-day treatment. Patients were then assessed according to the Fatigue Symptom Inventory, Chinese medicine symptoms score, Self-Rating Anxiety Scale, Self-Rating Depression Scale, Karnofsky Performance Status Scale, and Functional Assessment of Cancer Therapy-Lung. In addition, chemotherapy toxicity and tumor biomarkers were measured. Results: For NSCLC patients after chemotherapy, FRG extract significantly improved the FSI score, CM symptoms score, psychological status, physical conditions, and quality of life and reduced chemotherapy toxicity(P<0.01), but the expression levels of carcinoembryonic antigen, cytokeratin-19 fragments, and neuron-specific enolase were not significantly different between the chemotherapy alone and the FRG + chemotherapy groups or between pre-and post-treatments(P>0.05). Conclusions: This study demonstrated that FRG extract had an adjuvant effect on advanced NSCLC patients treated with chemotherapy. Further studies with a larger sample size will verify the current findings.
引用
收藏
页码:331 / 337
页数:7
相关论文
共 50 条
  • [31] Efficacy of Adjuvant Chemotherapy for Completely Resected Stage IB Non-Small Cell Lung Cancer
    Byun, M. K.
    Park, H. J.
    Park, H. S.
    Jeung, H.
    Cho, J. Y.
    Lee, S. S.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1982 - S1982
  • [32] NANOG as an adverse predictive marker in advanced non-small cell lung cancer treated with platinum-based chemotherapy
    Chang, Boksoon
    Park, Myung Jae
    Choi, Sue In
    In, Kwang Ho
    Kim, Chul Hwan
    Lee, Seung Hyeun
    ONCOTARGETS AND THERAPY, 2017, 10 : 4625 - 4633
  • [33] Stage IV non-small cell lung cancer.: Duration of chemotherapy for locally advanced non small cell lung cancers
    Vergnenegre, A.
    REVUE DES MALADIES RESPIRATOIRES, 2006, 23 (05) : S72 - S77
  • [34] Chemotherapy in Non-Small Cell Lung Cancer Patients Receiving Oxygen Therapy
    Watanabe, Keisuke
    Shinkai, Masaharu
    Tei, Yoshitaka
    Kaneko, Takeshi
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (10) : 587 - 590
  • [35] Echocardiography and cardiac biomarkers in patients with non-small cell lung cancer treated with platinum-based chemotherapy
    Omersa, Daniel
    Cufer, Tanja
    Marcun, Robert
    Lainscak, Mitja
    RADIOLOGY AND ONCOLOGY, 2017, 51 (01) : 15 - 22
  • [36] A slow disengagement from platinum-based chemotherapy for patients with advanced non-small cell lung cancer
    Ballas, MS
    Dennis, PA
    CANCER BIOLOGY & THERAPY, 2005, 4 (12) : 1316 - 1317
  • [37] Role of Pharmacists in Completion of Adjuvant Cisplatin-Vinorelbine Chemotherapy in Japanese Patients with Non-small Cell Lung Cancer
    Morimoto, Yoshihito
    Takei, Hidefumi
    Tachibana, Keisei
    Nakazato, Yoko
    Tanaka, Ryota
    Nagashima, Yasushi
    Watanabe, Kazuhiro
    Seki, Reisuke
    Shinohara, Takao
    Kondo, Haruhiko
    YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2018, 138 (03): : 437 - 442
  • [38] Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
    Shaw, A. T.
    Varghese, A. M.
    Solomon, B. J.
    Costa, D. B.
    Novello, S.
    Mino-Kenudson, M.
    Awad, M. M.
    Engelman, J. A.
    Riely, G. J.
    Monica, V.
    Yeap, B. Y.
    Scagliotti, G. V.
    ANNALS OF ONCOLOGY, 2013, 24 (01) : 59 - 66
  • [39] Preoperative thrombocytosis in surgically treated patients with non-small cell lung cancer
    Skorek, Pawel
    Stepien, Konrad
    Fila, Marcin
    Hauer, Jolanta
    Kuzdzal, Jaroslaw
    POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2018, 128 (09): : 512 - 517
  • [40] Thromboembolic events in patients with advanced stage non-small cell lung cancer treated with platinum-based chemotherapy: a prospective observational study
    Joshi, Amit
    Kate, Shruti
    Noronha, Vanita
    Patil, Vijay
    Trivedi, Vaishakhi
    Goud, Supriya
    More, Sucheta
    Bhairva, Sandeep
    Prabhash, Kumar
    ECANCERMEDICALSCIENCE, 2018, 12